G
Galecto D
D
GLTO
3.26000
USD
-0.19
(-5.51%)
مغلق
حجم التداول
6
الربح لكل سهم
-18
العائد الربحي
-
P/E
-0
حجم السوق
4,310,890
الأخبار المقالات
العنوان: Galecto Inc
القطاع: Healthcare
الصناعة: Biotechnology
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.